How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 2, 2014, Pages 303-309

  Huang, Bin Tao ^a   Tan, Yan ^b   Zhao, Wei Hong ^a   Zeng, Qing Chun ^b   Li, Bing Sheng ^c   Chen, Rui Lin ^d  

^a AFFILIATED HOSPITAL OF INNER MONGOLIA MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c Huizhou Medicine Institute   (China)

^d GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Bortezomib; Cyclophosphamide; Doxorubicin; Elderly; Multiple myeloma

Indexed keywords

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PYRAZINES; SURVIVAL RATE;

EID: 84895074167     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1570-6     Document Type: Article

References (17)

1. Anagnostopoulos A, Gika D, Symeonidis A, Zervas K, Pouli A, Repoussis P et al (2005) Multiple myeloma in elderly patients: prognostic factors and outcome. Eur J Haematol 75:370-375
2. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G et al (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European group for blood and marrow transplant. Br J Haematol 102:1115-1123
3. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412-3420
4. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M et al (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 28:4621-4629
5. Huang BT, Zeng QC, Yu J, Xiao Z, Li BS, Zhang CL et al (2012a) How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience. J Cancer Res Clin Oncol 138:125-132
6. Huang BT, Zeng QC, Yu J, Liu XL, Xiao Z, Zhu HQ (2012b) High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China. Med On
7. International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121(5):749-757
8. Kane RC, Farrell AT, Sridhara R, Pazdur R (2006) United States food and drug administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 12:2955-2960
9. Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N et al (2009) Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the international staging system (ISS): an analysis of the Greek myeloma study group (GMSG). Leukemia 23:1152-1157
10. Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O et al (2013) Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol 31:247-255
11. Palumbo A, Mateos MV, Bringhen S, San Miguel JF (2011) Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? Blood Rev 25:181-191
12. Rajkumar SV, Buadi F (2007) Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation. Best Pract Res Clin Haematol 20:665-680
13. Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H et al (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 30:2946-2955
14. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR et al (2007) A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 21:529-534
15. Tan D, Teoh G, Lau LC, Lim A, Lim TH, Yap KC et al (2010) An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era. Am J Hematol 85:752-756
16. Yang GZ, Chen WM (2010) Bortezomib-based regimen for the treatment of 110 multiple myeloma patients. Zhonghua Yi Xue Za Zhi 90:2671-2674
17. Zhao Y, Dou LP, Wang SH, Bo J, Wang QS, Huang WR et al (2010) The efficacy and safety of PAD and VAD regimens for untreated multiple myeloma. Zhonghua Nei Ke Za Zhi 49:762-764